Review
Oncology
Emaan Haque, Abdullah Esmail, Ibrahim Muhsen, Haneen Salah, Maen Abdelrahim
Summary: Gastric cancer is the fifth most common tumor worldwide. Recent advancements have been made in the diagnosis and treatment of the disease, including improvements in non-invasive diagnostic techniques and the identification of new therapeutic targets. A multidisciplinary approach and cytotoxic chemotherapy are the main treatment options currently available.
Review
Oncology
Ilana Schlam, Paolo Tarantino, Sara M. Tolaney
Summary: This article summarizes the resistance mechanisms to HER2-targeted treatments and discusses the potential strategies to overcome them in order to improve outcomes for breast cancer patients.
Review
Chemistry, Medicinal
Saloni Ramani, Sayalee Samant, Sonal M. Manohar
Summary: EGFR plays a significant role in cellular processes such as growth, survival, and differentiation. Its deregulation is implicated in various human malignancies, making it an attractive anticancer target. Current therapeutic strategies show some efficacy in inhibiting EGFR, but resistance limits their clinical benefit.
FUTURE MEDICINAL CHEMISTRY
(2022)
Review
Immunology
Parisa Shamshiripour, Fahimeh Hajiahmadi, Shahla Lotfi, Niloofar Robab Esmaeili, Amir Zare, Mahzad Akbarpour, Davoud Ahmadvand
Summary: This review discusses the underlying molecular mechanisms contributing to aberrant angiogenesis in glioblastoma and the clinical applications and limitations of anti-angiogenic immunotherapeutics, as well as the potential advantages and limitations of small interfering RNAs as next-generation therapeutics.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Khalil Saleh, Alexis Fernandez, Florence Pasquier
Summary: The outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) has dramatically improved in the past 20 years with the introduction of tyrosine kinase inhibitors and monoclonal antibodies. These treatments have shown great efficacy in young and fit patients, leading to questioning the reliance on chemotherapy and stem cell transplantation. They can also be safely used in elderly patients, who make up the majority of Ph+ ALL patients. This review focuses on the recent changes in the management of Ph+ ALL patients and the development of new therapeutic strategies.
Review
Oncology
Torben Frostrup Hansen, Camilla Qvortrup, Per Pfeiffer
Summary: Angiogenesis is a key element in the treatment strategy for colorectal cancer, with challenges in finding effective biomarkers and personalized treatments. The combination of immunotherapy and anti-angiogenic treatment brings new hope for patients.
Review
Oncology
Heidi M. Haikala, Pasi A. Janne
Summary: HER3, a pseudokinase member of the EGFR family, plays a crucial role in tumor progression and drug resistance. Despite being discovered over 30 years ago, therapeutic interventions targeting HER3 have not yet received clinical approval, leading to increasing preclinical and clinical trials.
CLINICAL CANCER RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Raffaele Borriello, Lucia Cerrito, Antonio Gasbarrini, Francesca Romana Ponziani
Summary: Anti-angiogenic drugs used in the treatment of advanced HCC have different pharmacokinetic characteristics and effectiveness. It is necessary to conduct more studies to understand the factors influencing pharmacokinetic parameters and improve individual therapeutic response. Additionally, the benefits and risks of systemic therapy for advanced HCC in patients with liver impairment should be evaluated.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2023)
Review
Biology
Terry W. Moody, Irene Ramos-Alvarez, Robert T. Jensen
Summary: Cancer growth is regulated by receptor tyrosine kinases (RTKs) and G-protein-coupled receptors (GPCRs). Different mutations in EGFR and NTSR1 can lead to abnormal cancer proliferation. The use of tyrosine kinase inhibitors and SR48692 as antagonists can impair the transactivation process and inhibit cancer growth.
Article
Multidisciplinary Sciences
Xin Yu Koh, Xiao Hui Koh, Diana Spiegelberg, Preeti Jha, Marika Nestor, Le-ann Hwang, Ban Xiong Tan, David Philip Lane
Summary: The RON receptor tyrosine kinase is a promising target for oncology and immunology. The development of potent and selective anti-RON antibodies with high affinity binding has the potential to inhibit tumor growth and enhance tumor immune rejection. These antibodies can also be used for immuno-positron emission tomography imaging and recognize universally exposed RON epitopes on the cell surface.
SCIENTIFIC REPORTS
(2022)
Article
Biotechnology & Applied Microbiology
Pablo Mando, Federico Waisberg, Rosario Pasquinelli, Sergio Rivero, Alexis Ostinelli, Florencia Perazzo
Summary: Around 20% of breast cancers are associated with amplification or overexpression of human epidermal growth factor receptor 2 (HER2). Anti-HER2-targeted agents, including monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) are the cornerstone of cancer therapeutic strategies. However, resistance to treatment remains a challenge in HER2-positive breast cancer, and the introduction of new agents has created awareness of potential adverse events, posing challenges in daily patient care.
ONCOTARGETS AND THERAPY
(2023)
Review
Biochemistry & Molecular Biology
Sunanda Singh, Hector J. J. Gomez, Shreya Thakkar, Samara P. P. Singh, Ashutosh S. S. Parihar
Summary: Anti-neoplastic agents for cancer treatment employ various mechanisms and when combined can effectively inhibit cancer growth. However, the development of acquired drug resistance often renders these agents ineffective. This study identifies at least 24 different anti-neoplastic agents that use the STAT3 signaling pathway to develop therapeutic resistance. Targeting STAT3 in combination with existing agents may be a successful strategy to prevent or overcome drug resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Francesco Piazza, Veronica Di Paolo, Greta Scapinello, Sabrina Manni, Livio Trentin, Luigi Quintieri
Summary: LPL is a rare subtype of B cell-derived non-Hodgkin lymphoma characterized by abnormal growth of transformed clonal lymphoplasmacytes and plasma cells. Despite progress in therapy, LPL is almost invariably incurable and exhibits a propensity towards development of therapy resistance. This review aims to describe the clinical and pathobiological features of LPL and analyze the mechanisms of drug resistance in this disease.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
James J. Kang, Albert Ko, Sang Hoon Kil, Jon Mallen-St. Clair, Daniel Sanghoon Shin, Marilene B. Wang, Eri S. Srivatsan
Summary: Receptor tyrosine kinases (RTKs) are cell surface receptors that bind growth factor ligands and initiate cellular signaling. Among the 20 classes of RTKs, 7 classes are linked to head and neck cancers (HNCs). The epidermal growth factor receptor (EGFR) is the most studied class of RTK, with overexpression observed in 20% of tumors and a variant III expression seen in 15% of aggressive chemoradiotherapy resistant HNCs. Current treatments include EGFR monoclonal antibodies and inhibitors targeting the EGFR, MAPK, and mTOR pathways, with immunotherapy showing effectiveness in a subset of patients with HNC. Combination therapy of immunotherapy and EGFR monoclonal antibodies is being explored to overcome EGFR resistance.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Review
Pharmacology & Pharmacy
Yazan Haddad, Marek Remes, Vojtech Adam, Zbynek Heger
Summary: The study utilized variations in 110 crystal structures to assemble eight distinct families highlighting the C-helix orientation in the N-lobe of the EGFR kinase domain. These families shared similar mutational profiles, ligand R-groups facing the C-helix, mutation sites, and DFG domain.
DRUG DISCOVERY TODAY
(2021)
Article
Oncology
N. J. Latino, M. Galotti, N. Cherny, E. G. E. de Vries, J-Y Douillard, D. Kaidarova, A. Ilbawi
Summary: The ESMO four-phase approach resulted in updating the Kazakhstan national essential cancer medicines list and cancer treatment protocols, leading to the removal of low-value or non-evidence-based medicines and an increase in budget for cancer care. This approach can improve access to medicines, expenditure efficiency, and sustainability of cancer systems, showcasing how collaboration between WHO and ESMO can positively impact patient care through sharing best practices and resources.
Review
Oncology
Sara Hone Lopez, Mathilde Jalving, Rudolf S. N. Fehrmann, Wouter B. Nagengast, Elisabeth G. E. de Vries, Jacco J. de Haan
Summary: The gut wall, as the largest immune organ, interacts with the immune system through gut microbiota. The composition of gut microbiota plays a role in the anticancer immune response on immune checkpoint inhibitors (ICI). However, the impact of gut wall characteristics on the response to ICI has been overlooked. This article provides an overview of markers to characterize the gut wall and interventions that can modulate these characteristics, and discusses the future utilization and study of these markers and interventions to improve ICI treatment strategies.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Jasper J. L. van Geel, Jorianne Boers, Sjoerd G. Elias, Andor W. J. M. Glaudemans, Erik F. J. de Vries, Geke A. P. Hospers, Michel van Kruchten, Evelien J. M. Kuip, Agnes Jager, Willemien C. Menke-van der Houven Van Oordt, Bert van der Vegt, Elisabeth G. E. de Vries, Carolina P. Schroder
Summary: The clinical validity of [F-18]FES-PET in determining tumor ER status in MBC patients has been established in this study. Qualitative assessment of whole-body [F-18]FES-PET shows high diagnostic accuracy in predicting ER expression in biopsied metastasis. Quantitative [F-18]FES uptake in the corresponding metastasis also has predictive value for ER immunohistochemistry. Meta-analysis suggests improved diagnostic performance with the addition of this study's data.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Linda N. Broer, Daan G. Knapen, Frans V. Suurs, Ingrid Moen, Danique Giesen, Stijn J. H. Waaijer, Baard Indrevoll, Christine Ellingsen, Alexander Kristian, Alan S. Cuthbertson, Derk-Jan A. de Groot, Patricia E. Cole, Elisabeth G. E. de Vries, Urs B. Hagemann, Marjolijn N. Lub-de Hooge
Summary: The study compares Zr-89-MSLN PET imaging with Th-227-MSLN treatment and finds that Zr-89-MSLN PET imaging reflects MSLN expression and matches Th-227-MSLN tumor uptake and biodistribution.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Editorial Material
Oncology
Sjoukje F. Oosting, Astrid A. M. van der Veldt, Rudolf S. N. Fehrmann, Corine H. GeurtsvanKessel, Rob S. van Binnendijk, Anne-Marie C. Dingemans, Egbert F. Smit, T. Jeroen N. Hiltermann, Gerco den Hartog, Mathilda Jalving, Tatjana T. Westphal, Arkajyoti Bhattacharya, Faye de Wilt, Annemarie Boerma, Lisanne van Zijl, Guus F. Rimmelzwaan, Pia Kvistborg, Cecile A. C. M. van Els, Nynke Y. Rots, Debbie van Baarle, John B. A. G. Haanen, Elisabeth G. E. de Vries
Article
Biochemistry & Molecular Biology
Karla A. Lee, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Bjork, Laura Kist de Ruijter, Federica Armanini, Francesco Asnicar, Aitor Blanco-Miguez, Ruth Board, Neus Calbet-Llopart, Lisa Derosa, Nathalie Dhomen, Kelly Brooks, Mark Harland, Mark Harries, Emily R. Leeming, Paul Lorigan, Paolo Manghi, Richard Marais, Julia Newton-Bishop, Luigi Nezi, Federica Pinto, Miriam Potrony, Susana Puig, Patricio Serra-Bellver, Heather M. Shaw, Sabrina Tamburini, Sara Valpione, Amrita Vijay, Levi Waldron, Laurence Zitvogel, Moreno Zolfo, Elisabeth G. E. de Vries, Paul Nathan, Rudolf S. N. Fehrmann, Veronique Bataille, Geke A. P. Hospers, Tim D. Spector, Rinse K. Weersma, Nicola Segata
Summary: An analysis of metagenomic sequencing of stool samples reveals the association between gut microbiome and response to immune checkpoint blockade therapy in melanoma patients. However, there is limited consistency in the microbiome-based signatures across different populations. Future studies should consider larger sample sizes and examine the complex interplay between clinical factors and the gut microbiome.
Review
Oncology
Annika Fendler, Elisabeth G. E. de Vries, Corine H. GeurtsvanKessel, John B. Haanen, Bernhard Wormann, Samra Turajlic, Marie von Lilienfeld-Toal
Summary: The efficacy and immunogenicity of COVID-19 vaccines in cancer patients are uncertain due to their exclusion from pivotal clinical trials. In this Review, the current knowledge on vaccine efficacy and immune responses in cancer patients is summarized, highlighting key factors that may affect vaccine efficacy in this population.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Article
Oncology
Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries
Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.
CLINICAL CANCER RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joyce van Sluis, Walter Noordzij, Elisabeth G. E. de Vries, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Ronald Boellaard
Summary: This study explores the influence of using manual segmentations versus an AI-based automated segmentation tool on calculating whole-body effective doses. The results show that using AI-based segmentations can save time and achieve higher similarity coefficients compared to manual segmentations. The whole-body effective doses show minimal differences for the six patients.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Article
Oncology
S. F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N. J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E. G. E. de Vries, M. Piccart, N. I. Cherny
Summary: This article discusses the importance of quality of life (QoL) data and quality assurance measures in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Through field testing and revision, a checklist consisting of four items was developed to ensure the reliability and clinical relevance of QoL data. Implementation of this checklist will facilitate objective and transparent decision making in the ESMO-MCBS scoring process.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G. E. de Vries, Andor W. J. M. Glaudemans, Philippe Aftimos, Geraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt
Summary: The purpose of this study was to investigate the use of [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]-fluoro-17(3-estradiol ([18F]FES) PET/CT imaging in patients with metastatic ER-positive breast cancer undergoing treatment with rintodestrant. The study found that absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the effect of therapy and continued mode of action of SERDs.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Laura Kist de Ruijter, Pim P. van de Donk, Jahlisa S. Hooiveld-Noeken, Danique Giesen, Sjoerd G. Elias, Marjolijn N. Lub-de Hooge, Sjoukje F. Oosting, Mathilde Jalving, Wim Timens, Adrienne H. Brouwers, Thomas C. Kwee, Jourik A. Gietema, Rudolf S. N. Fehrmann, Bernard M. Fine, Sandra M. Sanabria Bohorquez, Mahesh Yadav, Hartmut Koeppen, Jing Jing, Sebastian Guelman, Mark T. Lin, Michael J. Mamounas, Jeffrey Ryan Eastham, Patrick K. Kimes, Simon P. Williams, Alexander Ungewickell, Derk J. A. de Groot, Elisabeth G. E. de Vries
Summary: Immune checkpoint inhibitors (ICIs), by reinvigorating CD8(+) T cell mediated immunity, have revolutionized cancer therapy. However, the systemic distribution and pharmacodynamics of CD8(+) T cells in response to ICIs remains poorly understood. In this study, we used a zirconium-89-labeled, CD8-specific antibody PET tracer to characterize the dynamic distribution of CD8(+) T cells in patients with solid tumors before and after ICI therapy. The results revealed significant heterogeneity in CD8(+) T cell distribution and pharmacodynamics both between and within patients.
Article
Oncology
Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H. J. T. de Hingh, Frank J. P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G. E. de Vries, Carin A. Uyl-de Groot, Sabine Siesling
Summary: This study evaluated the changes in survival of patients with de novo metastatic solid cancers over the past 30 years. The proportion of M1 disease and net survival rates varied among different cancer types. Better preventive measures and early detection are needed to reduce the incidence of metastatic disease.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Multidisciplinary Sciences
Elena Garralda, Scott A. Laurie, Lesley Seymour, Elisabeth G. E. de Vries
Summary: Early detection of immunotherapy-induced tumor response is crucial, but therapy-induced pseudoprogression can make it complicated. A consensus guideline called iRECIST, a modification of RECIST version 1.1, was developed. This article explores the next steps required to test its validity and proposes novel approaches for response criteria.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Elisabeth G. E. de Vries, Josef Rueschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van Der Heijden, Giuseppe Viale
Summary: This study aimed to investigate tumor HER2 expression and its effects on T-DM1 treatment in patients with HER2-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. The results showed that some HER2-positive bladder cancer and pancreatic cancer patients responded well to T-DM1, and it also provided insight into the prevalence of HER2 positivity and expression patterns in these three non-breast tumor types.
